title: Overcoming target-mediated quinolone resistance in topoisomerase IV by introducing metal-ion-independent drug-enzyme interactions.
abstract: Quinolones, which target gyrase and topoisomerase IV, are the most widely prescribed antibacterials worldwide. Unfortunately, their use is threatened by the increasing prevalence of target-mediated drug resistance. Greater than 90% of mutations that confer quinolone resistance act by disrupting enzyme-drug interactions coordinated by a critical water-metal ion bridge. Quinazolinediones are quinolone-like drugs but lack the skeletal features necessary to support the bridge interaction. These compounds are of clinical interest, however, because they retain activity against the most common quinolone resistance mutations. We utilized a chemical biology approach to determine how quinazolinediones overcome quinolone resistance in Bacillus anthracis topoisomerase IV. Quinazolinediones that retain activity against quinolone-resistant topoisomerase IV do so primarily by establishing novel interactions through the C7 substituent, rather than the drug skeleton. Because some quinolones are highly active against human topoisomerase IIα, we also determined how clinically relevant quinolones discriminate between the bacterial and human enzymes. Clinically relevant quinolones display poor activity against topoisomerase IIα because the human enzyme cannot support drug interactions mediated by the water-metal ion bridge. However, the inclusion of substituents that allow quinazolinediones to overcome topoisomerase IV-mediated quinolone resistance can cause cross-reactivity against topoisomerase IIα. Therefore, a major challenge in designing drugs that overcome quinolone resistance lies in the ability to identify substituents that mediate strong interactions with the bacterial, but not the human, enzymes. On the basis of our understanding of quinolone-enzyme interactions, we have identified three compounds that display high activity against quinolone-resistant B. anthracis topoisomerase IV but low activity against human topoisomerase IIα.
authors.affiliation: Departments of †Biochemistry and ‡Medicine (Hematology/Oncology) and the §Vanderbilt Institute of Chemical Biology, Vanderbilt University School of Medicine , Nashville, Tennessee 37232-0146, United States.
authors.forename: Katie J
authors.initials: KJ
authors.lastname: Aldred
authors.forename: Heidi A
authors.initials: HA
authors.lastname: Schwanz
authors.forename: Gangqin
authors.initials: G
authors.lastname: Li
authors.forename: Sylvia A
authors.initials: SA
authors.lastname: McPherson
authors.forename: Charles L
authors.initials: CL
authors.lastname: Turnbough
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Kerns
authors.forename: Neil
authors.initials: N
authors.lastname: Osheroff
mesh_terms: D000900:Anti-Bacterial Agents / Q000737:chemistry* / Q000494:pharmacology; D000951:Antigens, Neoplasm / Q000737:chemistry / Q000235:genetics / Q000378:metabolism*; D001408:Bacillus anthracis / Q000737:chemistry / Q000187:drug effects / Q000201:enzymology / Q000235:genetics; D002413:Cations, Divalent; D053837:DNA Cleavage / Q000187:drug effects; D027101:DNA Topoisomerase IV / Q000037:antagonists & inhibitors* / Q000737:chemistry / Q000235:genetics / Q000378:metabolism; D004250:DNA Topoisomerases, Type II / Q000737:chemistry / Q000235:genetics / Q000378:metabolism*; D004269:DNA, Bacterial / Q000737:chemistry / Q000378:metabolism; D004268:DNA-Binding Proteins / Q000737:chemistry / Q000235:genetics / Q000378:metabolism*; D024881:Drug Resistance, Bacterial / Q000187:drug effects; D006801:Humans; D007700:Kinetics; D008274:Magnesium / Q000737:chemistry / Q000378:metabolism; D009154:Mutation; D052999:Quinazolinones / Q000737:chemistry* / Q000494:pharmacology; D015363:Quinolones / Q000737:chemistry* / Q000494:pharmacology; D011994:Recombinant Proteins / Q000737:chemistry / Q000235:genetics / Q000378:metabolism; D013045:Species Specificity; D013329:Structure-Activity Relationship; D014867:Water / Q000737:chemistry
chemical_list: D000900:Anti-Bacterial Agents; D000951:Antigens, Neoplasm; D002413:Cations, Divalent; D004269:DNA, Bacterial; D004268:DNA-Binding Proteins; D052999:Quinazolinones; D015363:Quinolones; D011994:Recombinant Proteins; D014867:Water; D027101:DNA Topoisomerase IV; D004250:DNA Topoisomerases, Type II; D008274:Magnesium
references.citation: J Mol Biol. 2000 Jul 14;300(3):481-91
references.pmid: 10884345
references.citation: Clin Infect Dis. 2005 Jul 15;41 Suppl 2:S113-9
references.pmid: 15942877
references.citation: J Biol Chem. 1989 Mar 15;264(8):4412-6
references.pmid: 2538443
references.citation: Biochemistry. 2012 Jan 10;51(1):370-81
references.pmid: 22126453
references.citation: Nat Struct Mol Biol. 2010 Sep;17(9):1152-3
references.pmid: 20802486
references.citation: Biochim Biophys Acta. 1998 Oct 1;1400(1-3):173-84
references.pmid: 9748560
references.citation: Biochem Mol Biol Educ. 2008;37(1):2-10
references.pmid: 19225573
references.citation: Annu Rev Biochem. 2001;70:369-413
references.pmid: 11395412
references.citation: Nucleic Acids Res. 2013 Apr;41(8):4628-39
references.pmid: 23460203
references.citation: Am J Med. 2005 Mar;118(3):259-68
references.pmid: 15745724
references.citation: J Antimicrob Chemother. 1994 Oct;34(4):465-83
references.pmid: 7868402
references.citation: Eur J Cancer. 1998 Sep;34(10):1514-21
references.pmid: 9893622
references.citation: Biochemistry. 1997 May 20;36(20):5934-9
references.pmid: 9166762
references.citation: Antimicrob Agents Chemother. 2007 Apr;51(4):1191-201
references.pmid: 17261623
references.citation: Clin Infect Dis. 2001 Mar 15;32 Suppl 1:S9-S15
references.pmid: 11249823
references.citation: Curr Med Chem Anticancer Agents. 2005 Jul;5(4):363-72
references.pmid: 16101488
references.citation: Microbiol Mol Biol Rev. 1997 Sep;61(3):377-92
references.pmid: 9293187
references.citation: Chem Biol. 2010 May 28;17(5):421-33
references.pmid: 20534341
references.citation: Antimicrob Agents Chemother. 2010 Jul;54(7):3011-4
references.pmid: 20404126
references.citation: Biochim Biophys Acta. 1998 Oct 1;1400(1-3):29-43
references.pmid: 9748489
references.citation: Drugs. 1999;58 Suppl 2:6-10
references.pmid: 10553698
references.citation: Curr Med Chem Anticancer Agents. 2001 May;1(1):1-25
references.pmid: 12678768
references.citation: Antimicrob Agents Chemother. 2011 May;55(5):2335-43
references.pmid: 21383100
references.citation: Antimicrob Agents Chemother. 2003 Jul;47(7):2362-5
references.pmid: 12821500
references.citation: Antimicrob Agents Chemother. 2008 Feb;52(2):385-92
references.pmid: 17724149
references.citation: J Biol Chem. 1998 Jul 10;273(28):17643-50
references.pmid: 9651360
references.citation: J Biol Chem. 1991 Aug 5;266(22):14585-92
references.pmid: 1650363
references.citation: J Biol Chem. 1992 Jul 5;267(19):13150-3
references.pmid: 1320012
references.citation: Antimicrob Agents Chemother. 1993 Oct;37(10):2179-86
references.pmid: 8257142
references.citation: Mol Gen Genet. 1988 Jan;211(1):1-7
references.pmid: 2830458
references.citation: Antimicrob Agents Chemother. 2004 Aug;48(8):3024-7
references.pmid: 15273116
references.citation: Antimicrob Agents Chemother. 2008 Nov;52(11):3915-21
references.pmid: 18765690
references.citation: Antimicrob Agents Chemother. 1998 Dec;42(12):3293-5
references.pmid: 9835531
references.citation: Curr Pharm Des. 2001 Mar;7(5):337-53
references.pmid: 11254893
references.citation: Curr Top Med Chem. 2009;9(11):981-98
references.pmid: 19747119
references.citation: Antimicrob Agents Chemother. 2009 Sep;53(9):3822-31
references.pmid: 19564360
references.citation: Biochim Biophys Acta. 1998 Oct 1;1400(1-3):45-61
references.pmid: 9748496
references.citation: Antimicrob Agents Chemother. 1989 Jun;33(6):886-94
references.pmid: 2548439
references.citation: J Antimicrob Chemother. 2004 Jul;54(1):90-4
references.pmid: 15190035
references.citation: Antimicrob Agents Chemother. 1992 Apr;36(4):751-6
references.pmid: 1323952
references.citation: J Bacteriol. 2010 Oct;192(19):5053-62
references.pmid: 20675481
references.citation: Antimicrob Agents Chemother. 2009 Jan;53(1):235-41
references.pmid: 18838592